Chemistry:Voglibose

Short description: Alpha-glucosidase inhibitor

Voglibose

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A10BF03 (WHO)
Identifiers
IUPAC name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number	83480-29-9 Y
PubChem CID	444020
DrugBank	DB04878 Y
ChemSpider	392046 Y
UNII	S77P977AG8
KEGG	D01665 Y
ChEMBL	ChEMBL476960 Y
Chemical and physical data
Formula	C10H21NO7
Molar mass	267.278 g·mol−1
3D model (JSmol)	Interactive image
SMILES OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
InChI InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 Y Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N Y
(verify)

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.

Efficacy

A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). It was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction.

Further reading

• "New therapeutic options in the treatment of diabetes mellitus". Clinical Pharmacology for nurses (17th ed.). Elsevier Limited, Churchill Livingstone. 2004. 
• Managing the Patient with Type II Diabetes. Aspen Publishers. 1997. pp. 62–63. ISBN 978-0-8342-1018-9. https://books.google.com/books?id=NiKUGHtQrvsC&dq=voglibose&pg=PA62.